Nexus Pharmaceuticals Receives FDA Approval for Tacrolimus Injection
Nexus Pharmaceuticals announces FDA approval of its Tacrolimus Injection 5 mg/mL, the first and only vial formulation available, enhancing treatment options for patients requiring immunosuppressive therapy.